Article Text

Download PDFPDF
Chlamydia trachomatis heat shock protein 60 (cHSP60) antibodies in women without and with tubal pathology using a new commercially available assay
  1. C J Bax1,2,
  2. P J Dörr1,
  3. J B Trimbos2,
  4. J Spaargaren3,
  5. P M Oostvogel4,
  6. A S Peña5,
  7. S A Morré5
  1. 1Department of Obstetrics and Gynaecology, MCH Westeinde Hospital, The Hague, Netherlands
  2. 2Department of Gynaecology, Leiden University Medical Center, Leiden, Netherlands
  3. 3Public Health Laboratory, Municipal Health Service, Amsterdam, Netherlands
  4. 4Department of Medical Microbiology, MCH Westeinde Hospital, The Hague, Netherlands
  5. 5Laboratory of Immunogenetics, Section Immunogenetics of Infectious Diseases, VU University Medical Center, Amsterdam, Netherlands

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Besides commercially available serological assays that detect antibodies to major outer membrane protein (MOMP)1 and lipopolysaccharide (LPS) “in-house” chlamydial heat shock protein 60 (cHSP60) assays are extensively used in assessing serological responses to urogenital Chlamydia trachomatis infection. Although comparison of the different “in-house” assays is difficult owing to a lack of standardisation, there is a consensus among the users of these assays that the anti-cHSP60 responses in women increase with the severity of C trachomatis associated disease, leading to the suggestion that the high amino acid sequence homology between chlamydial and human HSP60 results in autoimmune mediated fallopian tube damage. Owing to the significance of the possible association of the response to cHSP60 and progressive disease, a commercially produced assay that employs defined cHSP60 epitopes should allow for the comparison of results obtained in different laboratories, as well as forward the use of cHSP60 as a diagnostic tool if the assay proves to be relevant in predicting pathology or clinical outcome of a …

    View Full Text